Arm Symptoms and Overall Survival in Brazilian Patients with Advanced Breast Cancer

被引:0
|
作者
Bergmann, Anke [1 ,2 ]
Bourrus, Nathalia Santos [1 ,2 ]
de Carvalho, Cristiane Monteiro [2 ]
Dias, Ricardo de Almeida [1 ,2 ]
Nogueira Fabro, Erica Alves [2 ]
Sales, Nuria Silva [2 ]
de Aguiar, Suzana Sales [2 ]
机构
[1] Ctr Univ Augusto Motta, Bonsucesso, BR, Brazil
[2] Inst Nacl Canc, Sao Paulo, Brazil
关键词
Breast neoplasms; neoadjuvant therapy; arm symptoms; overall survival; advanced cancer; NEOADJUVANT;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Advanced breast cancer is a very frequent serious public health problem. Objective: This study aimed to analyze the prevalence of arm symptoms and overall survival in affected patients. Methodology: A retrospective cohort study was accomplished in 196 women presenting with advanced breast cancer. A descriptive analysis was carried out by and overall survival probabilities were calculated according to Kaplan-Meier method and Cox regression. Results: Thes included 196 woman had a medium age of 55.9 years, the majority being obese (71.3%) and having a IIIB clinical staging (52.3%). The most prevalent arm symptoms were pain (54.6%), paresthesia in upper limb (8.5%), lymphedema (> 200 ml) (6.6%), shoulder restriction (4.7%) and axillary web syndrome (0.6%). The median follow-up was 18.7 months (SD 7,33), 4.0% of the patients had metastasis and 31.6% were dead. The mean free disease survival was 20.4 months (95% CI 18.4-22.4), and the mean survival time was 26.3 months (95% CI 24.7-28.0). After adjusted the association with arm symptom and overall survival for clinical stage and presence of distant metastasis, the shoulder restriction was a predict variable, were represents the risk 2.59 for worse survival in compared with woman with no shoulder restriction (CI 95% 1.06-5.98). Conclusion: The population studied at this study presented high prevalence of complications earlier than neo adjuvant treatment. After controlling for effects of tumor variables, the shoulder restriction was statistically associated with poor overall survival after 2 years.
引用
收藏
页码:2939 / 2942
页数:4
相关论文
共 50 条
  • [21] Patient-reported pain and other symptoms as prognostic factors for overall survival (OS) in a phase III clinical trial of patients with advanced breast cancer
    Shen, Wei
    Wang, Ping
    Smyth, Emily Nash
    Bowman, Lee
    Peterson, Patrick
    John, William J.
    Melemed, Allen S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Symptoms as a predictor of survival in breast cancer patients.
    Brenner, D.
    Tammemagi, M.
    Nerenz, D.
    Krajenta, R.
    Nathanson, D.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 165 (11) : S9 - S9
  • [23] The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer
    Hiratsuka, Yusuke
    Kim, Yu Jung
    Suh, Sang-Yeon
    Won, Seon Hye
    Choi, Sung Eun
    LeBlanc, Thomas W.
    Kang, Beodeul
    Lee, Si Won
    Suh, Koung Jin
    Kim, Ji-Won
    Kim, Se Hyun
    Kim, Jin Won
    Lee, Keun-Wook
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (07) : 2338 - 2348
  • [24] Prognostic Value of NLR in Overall Survival of Patients with Advanced Lung Cancer
    Flores, C.
    Aguilar, A.
    Mas Lopez, L. A.
    Gutierrez Castaneda, J. M.
    Ruiz Mendoza, R.
    Pinillos-Ashton, L.
    Vallejos, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1993 - S1993
  • [25] Impact of molecular profiling on overall survival of patients with advanced ovarian cancer
    Herzog, Thomas J.
    Spetzler, David
    Xiao, Nick
    Burnett, Ken
    Maney, Todd
    Voss, Andreas
    Reddy, Sandeep
    Burger, Robert
    Krivak, Thomas
    Powell, Matthew
    Friedlander, Michael
    McGuire, William
    [J]. ONCOTARGET, 2016, 7 (15) : 19840 - 19849
  • [26] Overall survival of metastatic breast cancer patients - data from the PRAEGNANT breast cancer registry
    Taran, Florin-Andrei
    Fasching, Peter A.
    Volz, Bernhard
    Huober, Jens
    Overkamp, Friedrich
    Kolberg, Hans Christian
    Hadji, Peyman
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Lux, Michael P.
    Hartkopf, Andreas D.
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Geberth, Matthias
    Fersis, Nikos
    Abenhardt, Wolfgang
    Kurbacher, Christian
    Wuerstlein, Rachel
    Thomssen, Christoph
    Untch, Michael
    Janni, Wolfgang
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Schneeweiss, Andreas
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [27] CASCADE study: Longer overall survival in the novo versus recidivant patients with locally advanced/metastatic breast cancer
    Servitja, S.
    Zamora, P.
    Santaballa, A.
    Garcia, J.
    de Paz, L.
    Plata, Y.
    Garau, I.
    Florian, J.
    Chacon, I.
    de la Haba, J.
    Garcia, P.
    San Jose, B.
    Rodriguez-Villanueva, J.
    Orcajo, L.
    Martinez, E.
    Segui, M. A.
    [J]. CANCER RESEARCH, 2016, 76
  • [28] Overall survival following treatment with a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer
    Williams, William
    Dakhil, Shaker R.
    Calfa, Carmen
    Holmes, Jarrod P.
    Bhattacharya, Saveri
    Lukas, Jason
    Tan-Chui, Elizabeth
    Peoples, George E.
    Sunkari, Vivek G.
    Lacher, Markus D.
    Wiseman, Charles L.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [30] Nomograms to estimate long-term overall survival and breast cancer specific survival of patients with lumina! breast cancer
    Sun, W.
    Jiang, Y-Z
    Liu, Y-R
    Ma, D.
    Shao, Z-M
    [J]. CANCER RESEARCH, 2016, 76